 WESTBROOK, Maine, July 30, 2021 PRNewswire -- Achieves reported revenue growth of 30 and organic revenue growth of 25, driven by CAG Diagnostics recurring revenue growth of 30 as reported and 26 organic Delivers EPS of 2.34, representing 36 growth as reported and 33 on a comparable basis Increases 2021 revenue guidance to 3,170 million - 3,205 million, reflecting higher expectations for reported growth of 17 - 18.5 and organic growth of 14.5 - 16, supported by projected CAG Diagnostics recurring revenue growth of 18 - 19.5 as reported and 16 - 17.5 organic Raises 2021 EPS outlook to 8.20 - 8.36, reflecting an increase of 1 - 1.5 in the organic revenue growth outlook and expectations for higher operating margins of 28.6 - 29.1 IDEXX Laboratories, Inc. NASDAQ: IDXX, a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, today announced second quarter results, as well as an update on U.S. companion animal diagnostics sector trends. Second Quarter Results The Company reports revenues of 826 million for the second quarter of 2021, an increase of 30 as reported and 25 organically. 